Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies
Status PubMed-not-MEDLINE Jazyk angličtina Země Švýcarsko Médium electronic-ecollection
Typ dokumentu tisková chyba
PubMed
36605207
PubMed Central
PMC9809273
DOI
10.3389/fimmu.2022.1110388
Knihovny.cz E-zdroje
- Klíčová slova
- SCIG, antibodies, immunoglobulins, infections, infusion site reactions, primary immunodeficiencies,
- Publikační typ
- tisková chyba MeSH
[This corrects the article DOI: 10.3389/fimmu.2019.00040.].
Allergy and Asthma Center Inc Toledo OH United States
Division of Basic and Clinical Immunology University of California Irvine Irvine CA United States
Divisionof Hematology Department of Medicine University of Alberta Hospital Edmonton AB Canada
IMMUNOe Research Center Centennial CO United States
Midlands Pediatrics Papillion NE United States
Octapharma Pharmazeutika Produktionsges m b H Vienna Austria
Pediatric Pulmonary Associates of North Texas Frisco TX United States
Citace poskytuje Crossref.org
